Betta Pharmaceuticals (300558.SZ): Approval Notification for Clinical Trials of Injectable MCLA-129

Betta Pharmaceuticals (300558.SZ) announced that the company has received a "Drug Clinical Trial Approval Notice" (Notice No.: 2024LP02606) issued by the National Medical Products Administration (NMPA). The company's application for clinical trials of injection MCLA-129 for "advanced solid tumors (including but not limited to wild-type colorectal cancer, liver cancer, head and neck squamous cell carcinoma, pancreatic cancer, primary unknown adenocarcinoma and squamous cell carcinoma, among others)" has been approved by the NMPA.